Videos

Considerations for the selection of optimal therapy in patients with polycythemia vera, and how these novel agents may be sequenced in the event of disease progression.

Toni K. Choueiri, MD, discusses a key next step for using pembrolizumab in the treatment of renal cell carcinoma.

According to Allan Pickens, MD, surgery outcomes differ in minority patients and oncology surgeons are researching the issue.

Taking a closer look at the EMERALD trial, Dr Bardia shares key efficacy outcomes from the sub-group analyses 1) of patients with no prior chemotherapy and 2) comparing elacestrant to fulvestrant or AI.

Matthew P. Goetz, MD, discusses the background of the ELAINE-1 study examining lasofoxifene in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer harboring estrogen receptor 1 mutations.

Closing out their discussion, Drs Hetty Carraway and Eytan M. Stein highlight an ongoing clinical trial investigating a triplet therapy for AML.

Dr Stein explains clinical trial data on the use of magrolimab plus azacitidine for patients with TP53-mutated AML.

Lauren Welch, MSN, NP-C, AOCNP, describes how she approaches management of patients with NSCLC and known high PD-L1 expression while she waits for pending biomarker testing results.

Zosia Piotrowska, MD, and Michelle Shiller, DO, AP/CP, MGP, explain the frequency of the different biomarkers in NSCLC, and steps clinicians might take to ensure timely and effective molecular testing for their patients.

Scott Tykodi, MD, PhD, discusses using DFS as a primary end point in trials, as well as the usage of biomarkers.

Moshe Ornstein, MD, MA, discusses his approach to adjuvant therapy while treating patients with advanced clear cell RCC.

Nizar Tannir, MD, describes the data, criteria, and end points of the KEYNOTE-564 trial.

Dr Bardia discusses the mechanism of action of elacestrant, how elacestrant compares to other SERDS, and introduces the EMERALD trial.

Alexey Danilov, MD, PhD, discusses some targeted therapies being investigated in the relapsed/refractory chronic lymphocytic leukemia space.

Nitin Jain, MD, discusses clinical trials investigating allogeneic chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia and other hematologic malignancies.

Keerthi Gogineni, MD, MSHP, discusses the use of preoperative chemoimmunotherapy in patients with stage I triple negative breast cancer.

Chad Tang, MD, The University of Texas MD Anderson Cancer Center, discusses the design of the randomized, phase 2, basket EXTEND trial.

Yousef Zakharia, MD, discussed standard first-line treatment for renal cell carcinaoma.

A brief review of the identification and management of capillary leak syndrome in patients being treated for blastic plasmacytoid dendritic cell neoplasm.

Eric Jonasch, MD, discusses the 3-year follow-up of the LITESPARK-001 trial of belzutifan in patients with clear cell renal cell carcinoma.

Expert perspectives on the first-line use of tagraxofusp, a CD123-directed therapy, in patients with blastic plasmacytoid dendritic cell neoplasm.

Dr Carraway highlights some of the most urgent unmet needs for patients with higher-risk MDS.

Eytan M. Stein, MD, discusses how to treat patients with MDS who have IDH or TP53 mutations, and whether there is a role for targeted therapy in this patient population.

Centering discussion on polycythemia vera, Rami S. Komrokji, MD, and Pankit Vachhani, MD, share an in-depth review of cornerstone therapies in this setting.

Expert hematologist-oncologists share insight on the pathways driving myeloproliferative neoplasms and biomarkers that may be targeted with novel therapy.

Jonathan E. Rosenberg, MD, discusses what has been previously shown with enfortumab vedotin for patients with locally advanced metastatic urothelial cancer.

Lajos Pusztai, MD, DPhil, discusses the promise of neoadjuvant immunotherapy trials including the KEYNOTE-522 trial evaluating pembrolizumab plus chemotherapy in patients with triple-negative breast cancer.

David S. Hong, MD, discusses larotrectinib and its mechanism of action.

Adam Weiner, MD, discusses next steps for molecular testing in prostate cancer.

Joseph Mikhael, MD, discusses the ongoing impact of daratumumab in the treatment landscape of patients with multiple myeloma.